Literature DB >> 22170698

Restoration of C/EBPα in dedifferentiated liposarcoma induces G2/M cell cycle arrest and apoptosis.

Yuhsin V Wu1, Tomoyo Okada, Penelope DeCarolis, Nicholas Socci, Rachael O'Connor, Rula C Geha, C Joy Somberg, Cristina Antonescu, Samuel Singer.   

Abstract

Well-differentiated liposarcoma (WDLS) and dedifferentiated liposarcoma (DDLS) represent the most common biological group of liposarcoma, and there is a pressing need to develop targeted therapies for patients with advanced disease. To identify potential therapeutic targets, we sought to identify differences in the adipogenic pathways between DDLS, WDLS, and normal adipose tissue. In a microarray analysis of DDLS (n = 84), WDLS (n = 79), and normal fat (n = 23), C/EBPα, a transcription factor involved in cell cycle regulation and differentiation, was underexpressed in DDLS when compared to both WDLS and normal fat (15.2- and 27.8-fold, respectively). In normal adipose-derived stem cells, C/EBPα expression was strongly induced when cells were cultured in differentiation media, but in three DDLS cell lines, this induction was nearly absent. We restored C/EBPα expression in one of the cell lines (DDLS8817) by transfection of an inducible C/EBPα expression vector. Inducing C/EBPα expression reduced proliferation and caused cells to accumulate in G2/M. Under differentiation conditions, the cell proliferation was reduced further, and 66% of the DDLS cells containing the inducible C/EBPα expression vector underwent apoptosis as demonstrated by annexin V staining. These cells in differentiation conditions expressed early adipocyte-specific mRNAs such as LPL and FABP4, but they failed to accumulate intracellular lipid droplets, a characteristic of mature adipocytes. These results demonstrate that loss of C/EBPα is an important factor in suppressing apoptosis and maintaining the dedifferentiated state in DDLS. Restoring C/EBPα may be a useful therapeutic approach for DDLS.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22170698      PMCID: PMC3375024          DOI: 10.1002/gcc.21917

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  57 in total

Review 1.  Molecular regulation of adipocyte differentiation.

Authors:  R M Cowherd; R E Lyle; R E McGehee
Journal:  Semin Cell Dev Biol       Date:  1999-02       Impact factor: 7.727

2.  Down-regulation of histone deacetylases stimulates adipocyte differentiation.

Authors:  Eung Jae Yoo; Jun-Jae Chung; Sung Sik Choe; Kang Ho Kim; Jae Bum Kim
Journal:  J Biol Chem       Date:  2006-01-05       Impact factor: 5.157

3.  Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment.

Authors:  Maofu Fu; Mahadev Rao; Toula Bouras; Chenguang Wang; Kongming Wu; Xueping Zhang; Zhiping Li; Tso-Pang Yao; Richard G Pestell
Journal:  J Biol Chem       Date:  2005-02-14       Impact factor: 5.157

4.  Lack of C/EBP alpha gene expression results in increased DNA synthesis and an increased frequency of immortalization of freshly isolated mice [correction of rat] hepatocytes.

Authors:  H E Soriano; D C Kang; M J Finegold; M J Hicks; N D Wang; W Harrison; G J Darlington
Journal:  Hepatology       Date:  1998-02       Impact factor: 17.425

5.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

Authors:  G D Demetri; C D Fletcher; E Mueller; P Sarraf; R Naujoks; N Campbell; B M Spiegelman; S Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

6.  Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer.

Authors:  Sigal Gery; Sakae Tanosaki; Shikha Bose; Namrata Bose; Jay Vadgama; H Phillip Koeffler
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

7.  C/EBPalpha regulates formation of S-phase-specific E2F-p107 complexes in livers of newborn mice.

Authors:  N A Timchenko; M Wilde; G J Darlington
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

Review 8.  Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors.

Authors:  Peter F Johnson
Journal:  J Cell Sci       Date:  2005-06-15       Impact factor: 5.285

9.  PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes.

Authors:  Susan E Schadinger; Nancy L R Bucher; Barbara M Schreiber; Stephen R Farmer
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-01-11       Impact factor: 4.310

10.  Differential regulation of peroxisome proliferator activated receptor gamma1 (PPARgamma1) and PPARgamma2 messenger RNA expression in the early stages of adipogenesis.

Authors:  R Saladin; L Fajas; S Dana; Y D Halvorsen; J Auwerx; M Briggs
Journal:  Cell Growth Differ       Date:  1999-01
View more
  9 in total

Review 1.  The increasingly complex regulation of adipocyte differentiation.

Authors:  Sylvia P Poulos; Michael V Dodson; Melinda F Culver; Gary J Hausman
Journal:  Exp Biol Med (Maywood)       Date:  2015-12-07

2.  Upregulation of C/EBPα contributes to colorectal cancer growth, metastasis and indicates poor survival outcome.

Authors:  Lan Mi; Kai Hu; Xianzi Wen; Jing Sun; Aiwen Wu; Mingliang Wang; Minhua Zheng; Lu Zang; Jiafu Ji
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

Review 3.  Recent translational research into targeted therapy for liposarcoma.

Authors:  Rashi Bharat Patel; Ting Li; Zhichao Liao; Jivani Aakash Jaldeepbhai; H A Pavanika N V Perera; Sujani Kaushalya Muthukuda; Dholiya Hardeep Dhirubhai; Vaibhav Singh; Xiaoling Du; Jilong Yang
Journal:  Stem Cell Investig       Date:  2017-03-15

Review 4.  A tumor suppressor role for C/EBPα in solid tumors: more than fat and blood.

Authors:  A R Lourenço; P J Coffer
Journal:  Oncogene       Date:  2017-05-15       Impact factor: 9.867

5.  A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma.

Authors:  Christina V Angeles; Ana Velez; Tomoyo Okada; Samuel Singer; Jordan Rios; Bernadette Laxa; David Shum; Penelope D Ruiz; Yawei Shen; Irina Ostrovnaya; Rodrigo Gularte-Mérida; Benjamin A Nacev; Mark A Dickson; Hakim Djaballah
Journal:  Clin Cancer Res       Date:  2021-10-19       Impact factor: 13.801

Review 6.  Advances in the targeted therapy of liposarcoma.

Authors:  Zhonghai Guan; Xiongfei Yu; Haohao Wang; Haiyong Wang; Jing Zhang; Guangliang Li; Jiang Cao; Lisong Teng
Journal:  Onco Targets Ther       Date:  2015-01-05       Impact factor: 4.147

Review 7.  The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy.

Authors:  Santiago Rello-Varona; David Herrero-Martín; Laura Lagares-Tena; Roser López-Alemany; Núria Mulet-Margalef; Juan Huertas-Martínez; Silvia Garcia-Monclús; Xavier García Del Muro; Cristina Muñoz-Pinedo; Oscar Martínez Tirado
Journal:  Front Oncol       Date:  2015-04-07       Impact factor: 6.244

8.  Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice.

Authors:  Jiehua Zhou; Haitang Li; Xin Xia; Alberto Herrera; Nicolette Pollock; Vikash Reebye; Mikael H Sodergren; Stephanie Dorman; Bruce H Littman; Declan Doogan; Kai-Wen Huang; Robert Habib; David Blakey; Nagy A Habib; John J Rossi
Journal:  Mol Ther       Date:  2019-02-26       Impact factor: 11.454

Review 9.  Liposarcoma: Advances in Cellular and Molecular Genetics Alterations and Corresponding Clinical Treatment.

Authors:  Lingge Yang; Shiqi Chen; Peng Luo; Wangjun Yan; Chunmeng Wang
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.